Lipitor Adds Claims For High-Dose Use From TNT, IDEAL – But Label Is Mixed
Executive Summary
Lipitor (atorvastatin) has gained approval for five new indications based on the Treating to New Targets and Incremental Decrease in Endpoints Through Aggressive Lipid Lowering studies, but the updated labeling includes mixed statements about the benefits of treatment with higher doses of atorvastatin
You may also be interested in...
ACCORD Trial Complicates “Treating To New Targets” Theory In Diabetes
The large government-sponsored ACCORD trial in type 2 diabetes has stumbled in trying to show that driving down blood glucose to normal levels can improve cardiovascular outcomes in high-risk patients
ACCORD Trial Complicates “Treating To New Targets” Theory In Diabetes
The large government-sponsored ACCORD trial in type 2 diabetes has stumbled in trying to show that driving down blood glucose to normal levels can improve cardiovascular outcomes in high-risk patients
After Early Blow, Pfizer Prepares For Round Two Of Lipitor/Generic Zocor Fight
Although Lipitor has taken a beating in the run up to the launch of generics of Merck's Zocor, Pfizer is gearing up for a second round of movement in the cholesterol market, during which patients inadequately controlled on generic statins will switch to Lipitor, Pfizer CEO Hank McKinnell said June 13